SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease
Authors
Keywords
-
Journal
Nature Communications
Volume 11, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-01
DOI
10.1038/s41467-020-15983-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- NLRP3 Inflammasome and the IL-1 Pathway in Atherosclerosis
- (2018) Alena Grebe et al. CIRCULATION RESEARCH
- Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs
- (2018) Mikhail Kosiborod et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials
- (2016) Matteo Monami et al. ACTA DIABETOLOGICA
- CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
- (2016) Ele Ferrannini et al. DIABETES CARE
- Aberrant Inflammasome Activation Characterizes Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome
- (2016) Hong Yien Tan et al. JOURNAL OF IMMUNOLOGY
- Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
- (2016) Ralph A. DeFronzo et al. Nature Reviews Nephrology
- NLRP3 Inflammasome Expression and Activation in Human Atherosclerosis
- (2016) Geena Paramel Varghese et al. Journal of the American Heart Association
- Fasting and refeeding differentially regulate NLRP3 inflammasome activation in human subjects
- (2015) Javier Traba et al. JOURNAL OF CLINICAL INVESTIGATION
- The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome–mediated inflammatory disease
- (2015) Yun-Hee Youm et al. NATURE MEDICINE
- Inflammasomes: mechanism of action, role in disease and therapeutics
- (2015) Haitao Guo et al. NATURE MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Independent roles of the priming and the triggering of the NLRP3 inflammasome in the heart
- (2014) Stefano Toldo et al. CARDIOVASCULAR RESEARCH
- A New Equation to Estimate Glomerular Filtration Rate
- (2013) Andrew S. Levey et al. ANNALS OF INTERNAL MEDICINE
- The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia–reperfusion injury
- (2013) Øystein Sandanger et al. CARDIOVASCULAR RESEARCH
- Targeting Interleukin-1 in Heart Disease
- (2013) Benjamin W. Van Tassell et al. CIRCULATION
- 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
- (2013) David C. Goff et al. CIRCULATION
- NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
- (2010) Peter Duewell et al. NATURE
- Role for TNF in atherosclerosis? Lessons from autoimmune disease
- (2009) Gayle E. McKellar et al. Nature Reviews Cardiology
- Interleukin-1 Regulates Multiple Atherogenic Mechanisms in Response to Fat Feeding
- (2009) Janet Chamberlain et al. PLoS One
- TNF-α is an independent serum marker for proliferative retinopathy in type 1 diabetic patients
- (2008) Carin Gustavsson et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search